Cover Image
Market Research Report

Uveal Melanoma - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H1 2020

Published by GervanoRA Data Services LLP Product code 944097
Published Content info 157 Pages
Delivery time: 1-2 business days
Price
Back to Top
Uveal Melanoma - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H1 2020
Published: June 23, 2020 Content info: 157 Pages
Description

GervanoRA's pipeline analysis and opportunity assessment report "Uveal Melanoma - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics, H1 2020" analysed and assessed Uveal Melanoma pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Uveal Melanoma drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Uveal Melanoma disease area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Uveal Melanoma drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of Development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type. The report has also highlighted the universities and institutes working on the development of new innovative therapeutics for the treatment of Uveal Melanoma.

Our comprehensive analysis on the Uveal Melanoma drug pipeline identified 53 drug candidates undergoing different stages of development- from Pre-clinical stage to Phase 3 stage. Among these, a total of 44 drug candidates are in clinical stages of development and 09 molecules are in non-clinical stage of development. The drug pipeline consists of four (4) pipeline molecules in late clinical stage of development (Phase III), and a total of 17 pipeline molecules in early clinical stage of development (Phase I).

The report has covered a total of 32 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Market Dynamics with Coverage of Deals (Licensing, Partnering, Collaborations, Financing etc.)
  • Patent Analytics of Pipeline Molecules
  • Pipeline Analysis of all Drug Molecules and Estimated Pipeline Drug Approval Time lines of Late Clinical Stage (Phase 2 and Phase 3) Pipeline Drug Candidates
  • Clinical Stage Drug Candidates' Descriptions along with Development Milestones
  • Opportunity Assessments through Competitive Benchmarking
  • Evaluate Current and Future Competitive Landscape through Company Profiles
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

Table of Contents
Product Code: GERPH786

TABLE OF CONTENTS

CHAPTER 01: INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. ABOUT US: GERVANORA DATA SERVICES

CHAPTER 02: EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. KEY EVENTS IN THE UVEAL MELANOMA COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. OPPORTUNITIES

CHAPTER 03: DISEASE OVERVIEW

  • 3.1. DISEASE DEFINITION AND SYMPTOMS
  • 3.2. DISEASE CAUSE AND PATHOPHYSIOLOGY
  • 3.3. DISEASE DIAGNOSIS
  • 3.4. TREATMENT ALGORITHM AND GUIDELINES
  • 3.5. EPIDEMIOLOGY STUDIES
    • 3.5.1. GLOBAL AND HISTORICAL TRENDS
  • 3.6. EPIDEMIOLOGY FORECAST
    • 3.6.1. FORECAST METHODOLOGY AND ASSUMPTIONS
    • 3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

CHAPTER 04: MARKET DYNAMICS OF UVEAL MELANOMA THERAPIES

  • 4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
    • 4.1.1 DEALS ANALYTICS BY DEAL TYPE
      • 4.1.1.1. COLLABORATION DEALS
      • 4.1.1.2. LICENSING DEALS
      • 4.1.1.3. FINANCING DEALS
    • 4.1.2 DEALS ANALYTICS BY ANNUAL FREQUENCY
    • 4.1.3 DEALS ANALYTICS BY ACTIVE PLAYER
  • 4.2. PATENT ANALYSIS (EXPIRIES AND GENERICIZATION)
    • 4.2.1. PATENT ANALYTICS OF PIPELINE DRUGS

CHAPTER 05: PIPELINE DRUGS ANALYTICS OF UVEAL MELANOMA

  • 5.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
    • 5.1.1. PHASE III PIPELINE DRUGS
    • 5.1.2. PHASE II PIPELINE DRUGS
    • 5.1.3. PHASE I/II PIPELINE DRUGS
    • 5.1.4. PHASE I PIPELINE DRUGS
    • 5.1.5. PRE-CLINICAL PIPELINE DRUGS
  • 5.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY
  • 5.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
  • 5.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS
  • 5.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION
  • 5.6. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE
  • 5.7. PIPELINE DRUGS ANALYTICS BY TARGET RECEPTORS
  • 5.8. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

CHAPTER 06: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

  • 6.1. PHASE III PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 6.2. PHASE II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 6.3. PHASE I/II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 6.4. PHASE I PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

CHAPTER 07: ESTIMATED APPROVAL TIMELINES OF UVEAL MELANOMA PIPELINE DRUGS

  • 7.1. METHODOLOGY
  • 7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

CHAPTER 8: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

  • 8.1. EXTERNAL DEPENDENCIES
    • 8.1.1. BUSINESS R&D - INTERNAL INVESTMENT AND EXTERNAL FUNDING
  • 8.2. PIPELINE PORTFOLIO
  • 8.3. EXPECTED MARKET ENTRIES
  • 8.4. PATENTS AND EXCLUSIVITY
  • 8.5. MARKET DYNAMICS AND PARTNERING
  • 8.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
  • 8.7. COMPANY DEVELOPMENTS

CHAPTER 9: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 9.1. EMERGING COMPANIES
    • 9.1.1 EMERGING COMPANY PROFILES

LIST OF TABLES

  • TABLE 01: UVEAL MELANOMA REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: UVEAL MELANOMA AFFECTED POPULATION GLOBALLY
  • TABLE 03: COLLABORATION DEALS IN UVEAL MELANOMA THERAPEUTIC AREA
  • TABLE 04: LICENSING DEALS IN UVEAL MELANOMA THERAPEUTIC AREA
  • TABLE 05: FINANCING DEALS IN UVEAL MELANOMA THERAPEUTIC AREA
  • TABLE 06: IMMUNOCORE GRANTED PATENTS ANALYTICS
  • TABLE 07: IMMUNOCORE PATENT APPLICATIONS FILED
  • TABLE 08: ISSUED PATENTS ANALYTICS OF BIOMED VALLEY DISCOVERIES
  • TABLE 09: BIOMED VALLEY DISCOVERIES PATENT APPLICATIONS FILED
  • TABLE 10: GLOBAL PATENTS OF BIOMED VALLEY DISCOVERIES
  • TABLE 11: GRANTED PATENT ANALYTICS OF AURA BIOSCIENCES
  • TABLE 12: AURA BIOSCIENCES PATENT APPLICATIONS FILED
  • TABLE 13: GRANTED PATENTS ANALYTICS OF PROVECTUS BIOPHARMACEUTICALS
  • TABLE 14: UVEAL MELANOMA PIPELINE DRUGS BY STAGE OF DEVELOPMENT
  • TABLE 15: UVEAL MELANOMA PHASE III PIPELINE MOLECULES
  • TABLE 16: UVEAL MELANOMA PHASE II PIPELINE MOLECULES
  • TABLE 17: UVEAL MELANOMA PHASE I/II PIPELINE MOLECULES
  • TABLE 18: UVEAL MELANOMA PHASE I PIPELINE MOLECULES
  • TABLE 19: PRECLINICAL STAGE DRUG CANDIDATES FOR UVEAL MELANOMA
  • TABLE 20: LIST OF PIPELINE MOLECULES OF PARENTERAL ROUTE OF ADMINISTRATION
  • TABLE 21: LIST OF PIPELINE MOLECULES OF ORAL ROUTE OF ADMINISTRATION
  • TABLE 22: PIPELINE DRUGS AFFECTING ON T-CELL RECEPTORS
  • TABLE 23: LIST OF PIPELINE DRUGS OF KINASE INHIBITORS
  • TABLE 24: LIST OF PIPELINE MOLECULES WITH THEIR MECHANISM OF ACTIONS
  • TABLE 25: LIST OF PIPELINE DRUGS WITH THEIR MOLECULE TYPE
  • TABLE 26: LIST OF PIPELINE MOLECULES WITH THEIR MOLECULAR TARGETS
  • TABLE 27: UVEAL MELANOMA PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
  • TABLE 28: REGION WISE STATISTICS, COMPANY COUNT WITH COUNT OF UVEAL MELANOMA PIPELINE CANDIDATES
  • TABLE 29: DEVELOPMENT MILESTONES OF MELPHALAN HYDROCHLORIDE WITH HDS
  • TABLE 30: DEVELOPMENT MILESTONES OF SELUMETINIB
  • TABLE 31: DEVELOPMENT MILESTONES OF TEBENTAFUSP (IMCGP100)
  • TABLE 32: DEVELOPMENT MILESTONES OF ULIXERTINIB
  • TABLE 33: GERVANORA ESTIMATED APPROVAL TIMELINES V/S ACTUAL APPROVAL DATE
  • TABLE 34: UVEAL MELANOMA PIPELINE DRUGS (PHASE III AND PHASE II) ESTIMATED APPROVAL TIMELINES
  • TABLE 35: US PATENTS PORTFOLIO OF PROVECTUS BIOPHARMACEUTICALS
  • TABLE 36: RANKING OF TOP EMERGING COMPANIES BASED ON REGULATORY ALLOWANCES
  • TABLE 37: PIPELINE ASSETS OF IMMUNOCORE WITH RESPECT TO ONCOLOGY TREATMENTS
  • TABLE 38: PIPELINE ASSETS OF IMMUNOCORE WITH RESPECT TO INFECTIOUS DISEASE TREATMENTS
  • TABLE 39: PATENTS GRANTED TO IMMUNOCORE
  • TABLE 40: PATENT APPLICATIONS FILED BY IMMUNOCORE
  • TABLE 41: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OFIMMUNOCORE
  • TABLE 42: PRESENTATIONS AND EVENTS OF IMMUNOCORE
  • TABLE 43: PIPELINE ASSETS OF DELCATH SYSTEMS
  • TABLE 44: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF DELCATH SYSTEMS
  • TABLE 45: PRESENTATIONS AND EVENTS OF DELCATH SYSTEMS
  • TABLE 46: PIPELINE ASSETS OF IDEAYA BIOSCIENCES WITH RESPECT TO KINASE
  • TABLE 47: PIPELINE ASSETS OF IDEAYA BIOSCIENCES WITH RESPECT TO SYNTHETIC LETHALITY
  • TABLE 48: RESEARCH AND DEVELOPMENT ACTIVITIES OF IDEAYA BIOSCIENCES
  • TABLE 49: RECENT DEVELOPMENTS OF IDEAYA BIOSCIENCES
  • TABLE 50: PRESENTATIONS AND EVENTS OF IDEAYA BIOSCIENCES
  • TABLE 51: PIPELINE ASSETS OF BIOMED VALLEY DISCOVERIES
  • TABLE 52: PATENTS ISSUED TO BIOMED VALLEY DISCOVERIES IN THE U.S
  • TABLE 53: PATENT APPLICATIONS FILED BY BIOMED VALLEY DISCOVERIES IN THE U.S
  • TABLE 54: PATENTS AND PATENT APPLICATIONS FILED BY BIOMED VALLEY DISCOVERIES OTHER THAN THE U.S
  • TABLE 55: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF BIOMED VALLEY DISCOVERIES
  • TABLE 56: PRESENTATIONS AND EVENTS OF BIOMED VALLEY DISCOVERIES
  • TABLE 57: PUBLICATIONS OF BIOMED VALLEY DISCOVERIES
  • TABLE 58: PATENTS ISSUED TO AURA BIOSCIENCES
  • TABLE 59: PATENT APPLICATIONS FILED BY AURA BIOSCIENCES
  • TABLE 60: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OFAURA BIOSCIENCES
  • TABLE 61: PRESENTATIONS AND EVENTS OF AURA BIOSCIENCES
  • TABLE 62: PUBLICATIONS OFAURA BIOSCIENCES
  • TABLE 63: PIPELINE ASSETS OF REPLIMUNE
  • TABLE 64: RESEARCH AND DEVELOPMENT ACTIVITES OF REPLIMUNE
  • TABLE 65: PIPELINE ASSETS OF FARON PHARMACEUTICALS
  • TABLE 66: RESEARCH AND DEVELOPMENT ACTIVITIES OF FARON PHARMACEUTICALS
  • TABLE 67: RECENT DEVELOPMENTS OF FARON PHARMACEUTICALS
  • TABLE 68: PRESENTATIONS AND EVENTS OF FARON PHARMACEUTICALS
  • TABLE 69: PIPELINE ASSETS OF PROVECTUS BIOPHARMACEUTICALS
  • TABLE 70: US PATENTS PORTFOLIO OF PROVECTUS BIOPHARMACEUTICALS
  • TABLE 71: RESEARCH AND DEVELOPMENT AND PRESENTATIONS OF PROVECTUS BIOPHARMACEUTICALS
  • TABLE 72: RECENT DEVELOPMENTS OF PROVECTUS BIOPHARMACEUTICALS
  • TABLE 73: PIPELINE ASSETS OF AEGLEA BIOTHERAPEUTICS
  • TABLE 74: RESEARCH AND DEVELOPMENT ACTIVITIES OF AEGLEA BIOTHERAPEUTICS
  • TABLE 75: RECENT DEVELOPMENTS OF AEGLEA BIOTHERAPEUTICS
  • TABLE 76: PRESENTATIONS AND EVENTS OF AEGLEA BIOTHERAPEUTICS
  • TABLE 77: PIPELINE ASSETS OF INVENTIVA PHARMA
  • TABLE 78: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF INVENTIVA PHARMA
  • TABLE 79: PRESENTATION AND EVENTS OF INVENTIVA PHARMA
  • TABLE 80: PIPELINE ASSETS OF AEGLEA BIOTHERAPEUTICS
  • TABLE 81: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF BELLICUM PHARMACEUTICALS
  • TABLE 82: PRESENTATIONS AND EVENTS OF BELLICUM PHARMACEUTICALS
  • TABLE 83: PATENTS ISSUED TO EXELIXIS IN THE U.S
  • TABLE 84: PATENTS ISSUED TO EXELIXIS IN EUROPE
  • TABLE 85: RESEARCH AND DEVELOPMENT ACTIVITIES OF EXELIXIS
  • TABLE 86: RECENT DEVELOPMENTS OF EXELIXIS
  • TABLE 87: PRESENTATIONS AND EVENTS OF EXELIXIS
  • TABLE 88: PIPELINE ASSETS OF IOVANCE BIOTHERAPEUTICS
  • TABLE 89: RESEARCH AND DEVELOPMENT ACTIVITES OF IOVANCE BIOTHERAPEUTICS
  • TABLE 90: RECENT DEVELOPMENTS OF IOVANCE BIOTHERAPEUTICS
  • TABLE 91: PRESENTATION AND EVENTS OF IOVANCE BIOTHERAPEUTICS

LIST OF FIGURES

  • FIGURE 01: KEY EVENTS IN THE UVEAL MELANOMA COMPETITIVE SPACE
  • FIGURE 02: UVEAL MELANOMA DEAL ANALYTICS BY DEAL TYPE
  • FIGURE 03: UVEAL MELANOMA DEAL ANALYTICS BY DEAL FREQUENCY TILL MAY 2020
  • FIGURE 04: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D
  • FIGURE 05: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT
  • FIGURE 06: UM DRUGS PIPELINE ANALYTICS BY ROA
  • FIGURE 07: UM DRUGS PIPELINE ANALYTICS BY PARENTERAL ROA
  • FIGURE 08: PARENTERAL DRUGS PIPELINE ANALYTICS BY HSD
  • FIGURE 09: ORAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 10: TOTAL PIPELINE MOLECULES V/S DRUG CLASSES
  • FIGURE 11: PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 12: UVEAL MELANOMA PIPELINE DRUGS BIOLOGICALS VS SMALL MOLECULES
  • FIGURE 13: UVEAL MELANOMA PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE VS STAGE OF DEVELOPMENT
  • FIGURE 14: UVEAL MELANOMA COMPANIES (NUMBER, PERCENT SHARE)
  • FIGURE 15: GEOGRAPHICAL CATEGORIZATION OF COMPANIES WORKING ON UVEAL MELANOMA
  • FIGURE 16: COUNT OF COMPANIES FOCUSED ON CANCER BASED THERAPIES
  • FIGURE 17: RESEARCH AND DEVELOPMENT EXPENSES OF TOP 5 COMPANIES IN $M
  • FIGURE 18: EXTERNAL FUNDING RECEIVED BY THE COMPANIES IN $M
  • FIGURE 19: PIPELINE PORTFOLIO WITH (NUMBER OF MOLECULES)
  • FIGURE 20: EXPECTED MARKET ENTRY WITH RESPECT TO DRUG CANDIDATES TREATING UVEAL MELANOMA
  • FIGURE 21: TIME LINE OF PATENT EXPIRIES WITH RESPECT TO UVEAL MELANOMA TREATMENTS
  • FIGURE 22: RANKING TOP 5 EMERGING COMPANIES BASED ON THEIR PARTNERING ACTIVITIES
  • FIGURE 23: R&D EXPENSES FOR THE FINANCIAL YEARS OF 2018 AND 2019 BY DELCATH SYSTEMS IN $K
  • FIGURE 24: R&D EXPENSES FOR THE FINANCIAL YEARS OF 2017, 2018 AND 2019 BY IDEAYA BIOSCIENCES IN $K
  • FIGURE 25: R&D EXPENSES FOR THE FINANCIAL YEARS OF 2017, 2018 AND 2019 BY AEGLEA BIOTHERAPEUTICS IN $K
  • FIGURE 26: R&D EXPENSES FOR THE FINANCIAL YEARS OF 2018 AND 2019 BY BELLICUM PHARMACEUTICALS IN $K
  • FIGURE 27: R&D EXPENSES FOR THE FINANCIAL YEARS OF 2018 AND 2019 BY EXELIXIS IN $K
  • FIGURE 28: R&D EXPENSES FOR THE FINANCIAL YEARS OF 2018 AND 2019 BY IOVANCE BIOTHERAPEUTICS IN $K
Back to Top